For many people with knee osteoarthritis, the progression is familiar. First comes pain after activity. Then morning stiffness. Then the slow reorganisation of daily life around a joint that no longer cooperates. Stairs become a calculation. Long walks get shortened.
Most people searching for alternatives have already tried the standard options. Anti-inflammatories, corticosteroid injections, physiotherapy — these help, but their effect has limits. The underlying damage continues regardless. It is at this point that patients begin asking whether anything else exists.
What happens inside the knee in osteoarthritis
Osteoarthritis (OA) is the progressive breakdown of articular cartilage — the smooth tissue lining the knee joint. Cartilage has almost no capacity for self-repair. It contains no blood vessels and very few regenerative cells. Once it begins to deteriorate, the process tends to continue.
As cartilage thins, the surrounding joint responds. The synovial membrane becomes inflamed. Fluid accumulates. Bony growths called osteophytes form along joint margins. Pain originates not from cartilage itself — which has no nerve supply — but from the inflamed tissue and exposed bone beneath it.
OA is graded I–IV on the Kellgren-Lawrence scale. Grade II and III represent the stage where most patients seek alternatives: damage is visible on imaging, but the joint has not yet reached complete structural failure.
Why conventional treatments have limits
Standard treatments manage symptoms effectively. NSAIDs reduce pain. Corticosteroid injections address inflammation. Hyaluronic acid injections restore some joint lubrication. Physiotherapy builds supportive muscle strength. For severe, end-stage disease, total knee replacement is one of the most reliable surgical procedures available.
What none of these does is address the underlying biological process. They do not slow cartilage loss. Some evidence suggests repeated corticosteroid injections may accelerate it. The joint continues to deteriorate even when symptoms are controlled.
This gap — the absence of any treatment that targets the biology of the disease itself — is what led researchers to investigate regenerative approaches.
What are UC-MSCs and how might they help?
What they are and where they come from
Umbilical cord–derived mesenchymal stem cells (UC-MSCs) are isolated from Wharton’s jelly — connective tissue within the umbilical cord — collected after healthy, consented births. They are biologically younger than adult-derived stem cells. They carry a lower immunogenic profile. They are prepared in standardised, quality-tested batches before clinical use.
How they act on the knee
UC-MSCs do not replace cartilage. They act more like a biological messaging service. They release molecules — growth factors, cytokines, extracellular vesicles — that instruct surrounding tissue to reduce inflammation and support repair. They suppress the pro-inflammatory mediators most active in arthritic joints: TNF-α, IL-1β, and IL-6. When injected into the joint, they respond to chemical signals from damaged tissue and migrate toward sites of greatest inflammation.
The goal is not structural rebuilding. It is reducing the inflammatory environment that drives ongoing damage — and creating conditions in which the body’s own limited repair capacity can operate more effectively.
What the research currently shows
The clinical evidence for MSC therapy in knee OA has grown steadily. Multiple Phase 1 and Phase 2 trials report consistent improvements in pain and function at 6 to 12 months. A smaller number of randomised controlled trials show meaningful advantages over hyaluronic acid injections, with some imaging studies suggesting cartilage preservation in responding patients.
The evidence is encouraging — but early-stage. Most studies involve small patient numbers and short follow-up periods. Larger Phase 3 trials are still needed to confirm efficacy and identify which patients respond best. Patients should understand this distinction: promising preliminary data is not the same as established clinical proof.
What to expect: the treatment process
Assessment and preparation
Treatment begins with a full consultation. This includes reviewing imaging, prior treatments, current health status, and disease severity. Not every patient is a suitable candidate. This assessment determines whether to proceed and what to realistically expect.
The procedure
UC-MSCs are delivered by intra-articular injection — directly into the knee joint — typically under ultrasound guidance. The injection takes minutes. Most patients return home the same day. There is no surgical recovery period.
Timeline for results
Most cells are undetectable within days to a few weeks of injection. Effects arise from the biological signals released during that window — not from permanent cell presence. Patients who respond typically notice early changes at six to twelve weeks. More meaningful improvement develops over three to six months.
For patients considering UC-MSC therapy in Bangkok, EDNA Wellness applies GMP-certified cells from a TISTR-affiliated laboratory, with each batch verified by a Certificate of Analysis. Clinical programmes are overseen by board-certified neurosurgeons and orthopaedic specialists.
Safety and who is a suitable candidate
Published trials report a consistently favourable safety profile. Side effects are typically mild: brief soreness or swelling at the injection site, occasional fatigue in the days following treatment. Serious adverse events have been rare.
UC-MSC therapy is most appropriate for Grade II–III osteoarthritis — patients who have had an incomplete response to conventional care and are not yet at the stage where surgery is the only option. Patients with active joint infection, active malignancy, or significant systemic illness are generally not considered suitable. Grade IV (bone-on-bone) disease is unlikely to benefit meaningfully from a biologically-targeted intervention. A thorough medical evaluation is essential before any decision is made.
What to look for in a stem cell provider
Not all providers operate to the same standard. When evaluating a clinic, look for: GMP-certified cells with a Certificate of Analysis available per batch; physician oversight from relevant specialists; ultrasound-guided delivery; and honest communication about the evidence level — including its limits.
Be cautious of any provider who guarantees outcomes, avoids discussing limitations, or does not conduct a proper patient assessment before recommending treatment.
This article is for educational purposes only and does not constitute medical advice. Stem cell therapy for knee osteoarthritis is an emerging intervention, not a standard-of-care treatment. Outcomes vary between individuals. Readers are encouraged to discuss any treatment decision with their own physician.
References
- Lamo-Espinosa JM, et al. 2018. Intra-articular injection of mesenchymal stem cells versus hyaluronic acid in knee osteoarthritis. Journal of Translational Medicine, 16, 213. https://link.springer.com/article/10.1186/s12967-018-1591-7
- Vega A, et al. 2015. Treatment of knee osteoarthritis with allogeneic bone marrow mesenchymal stem cells: a randomized controlled trial. Transplantation, 99(8), 1681–1690. https://journals.lww.com/transplantjournal/abstract/2015/08000/treatment_of_knee_osteoarthritis_with_allogeneic.27.aspx
- Pas HIMFL, et al. 2017. Stem cell injections in knee osteoarthritis: a systematic review. British Journal of Sports Medicine, 51(15), 1125–1133. https://bjsm.bmj.com/content/51/15/1125
- National Institute of Arthritis and Musculoskeletal and Skin Diseases. Osteoarthritis. NIH. https://www.niams.nih.gov/health-topics/osteoarthritis